THOUSAND
OAKS, Calif., Sept. 23,
2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a
webcasted call for the investment community at 1:30 p.m. PT on
Tuesday, Sept. 24, 2024, to discuss
new topline clinical data from the rocatinlimab (AMG 451/KHK4083)
and UPLIZNA® (inebilizumab-cdon) Phase 3 programs.
Jay Bradner, executive vice
president of Research and Development and chief scientific officer
at Amgen, and other members of the Amgen team will participate. The
webcast will be broadcast over the internet simultaneously and will
be available to members of the news media, investors and the
general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences, can be found on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the event.
About Amgen
Amgen discovers, develops, manufactures
and delivers innovative medicines to help millions of patients in
their fight against some of the world's toughest diseases. More
than 40 years ago, Amgen helped to establish the biotechnology
industry and remains on the cutting-edge of innovation, using
technology and human genetic data to push beyond what's known
today. Amgen is advancing a broad and deep pipeline that builds on
its existing portfolio of medicines to treat cancer, heart disease,
osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the "World's Most Innovative
Companies" by Fast Company and one of "America's Best Large
Employers" by Forbes, among other external recognitions. Amgen
is one of the 30 companies that comprise the Dow Jones Industrial
Average®, and it is also part of the Nasdaq-100
Index®, which includes the largest and most innovative
non-financial companies listed on the Nasdaq Stock Market based on
market capitalization.
For more information, visit Amgen.com and follow Amgen on X,
LinkedIn, Instagram, TikTok, YouTube and Threads.
CONTACT: Amgen, Thousand
Oaks
Elissa Snook, 609-251-1407
(media)
Justin Claeys, 805-313-9775
(investors)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amgen-to-host-conference-call-to-discuss-new-topline-data-in-inflammation-and-rare-disease-302256043.html
SOURCE Amgen
